RVPH

Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

Reviva Pharmaceuticals Holdings Inc. (RVPH) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 2.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -6.0
Rev Growth YoY 0.0%
Gross Margin 0.0%
Price Return 3M -47.9%
Price Return 12M -95.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.0
ROE -256.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-03 C+ (2.7) C (2.4) C- (2.0) C (2.4) C- (2.0) C (2.3)